유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

biofrontera bioscience gmbh - 5-aminolevulínovej kyseliny - keratosis, actinic; carcinoma, basal cell - antineoplastické činidlá - liečba v súvislosti s keratóza miernej až stredne závažnosti na tvár a pokožku hlavy (olsen stupeň 1-2; pozri oddiel 5. 1) a z oblasti cancerization v dospelí. ošetrenie povrchových a/alebo z tvárnej bazálneho bunkového karcinómu, ktoré sú nevhodné pre chirurgická liečba vzhľadom na možné súvislosti s liečbou chorobnosti a/alebo zlá, kozmetické výsledky u dospelých.

슬로바키아 - 슬로바키아어 - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

norbrook laboratories ltd., Írsko - inj.

유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. pozri časti 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastické činidlá - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.

유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastické činidlá - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

유럽 연합 - 슬로바키아어 - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - ostatné dermatologické prípravky - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

슬로바키아 - 슬로바키아어 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bioscience gmbh walsmühler straße 18 d-19073 dümmer nemecko -

슬로바키아 - 슬로바키아어 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bioscience gmbh walsmühler straße 18 d-19073 dümmer nemecko -

슬로바키아 - 슬로바키아어 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bioscience gmbh walsmühler straße 18 d-19073 dümmer nemecko -

슬로바키아 - 슬로바키아어 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

elem magdalena pakulska, poľsko - cytiziniklín (cytizín) - 87 - varia i